Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic HIPEC After Radical Surgery for Locally Advanced Gastric Cancer
NCT06525714Phase 1Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Aug 2024
- Primary completion
- Jul 2029
- Modality
- Nanoparticles, Small Molecules
01
Overview
Phase 1, randomised, open-label trial of Cisplatin micelle injection (HA132) in gastric adenocarcinoma (2 arms), sponsored by The First Hospital of Jilin University. Primary endpoint: 3-year overall survival rate. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT06525714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06525714.